Study to Determine Effect of Exendin-9,39 Infusion on Insulin Secretion

Overview

About this study

The purpose of this study is to determine the effect of duration of exendin-9,39 infusion on insulin secretion.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

Inclusion Criteria:

  • Previous study participants.
  • Eligible subjects willing too come to the CRTU for a screening visit.

Exclusion Criteria:

  • Age <20 or >65.
  • BMI <18 or >35 Kg/M2.
  • For female subjects a positive pregnancy test.
  • Any systemic illness.
  • History of chronic medical illnesses.
  • Any medication that could affect glucose metabolism
  • Prior abdominal surgery other than cholecystectomy, appendectomy or tubal ligation.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Adrian Vella, M.D.

Closed-enrolling by invitation

What is this? (?)
"Close"
Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.

Contact information:

Jeanette Laugen

(507)255-8110

Laugen.Jeanette@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20440973

Mayo Clinic Footer